Werner Hacke, MD, PhD
Professor of the Department of Neurology, University of Heidelberg, Germany
Prof. Hacke gives an overview on the changes Actilyse® has made to acute stroke management since the licensing, including the extension of the guideline time window for thrombolysis. As the principle investigator of the ECASS trials, he talked about the importance of the results of these trials and how they have impacted clinical practice. He also provides an insight into the new ECASS 4 study.